>>> US Early premarket gappers

Early premarket gappers
Gapping up: JCP +20.3%, GBX +9.5%, WLT +9.4%, FRO +8.9%, SONC +5.2%, PBR +2.7%, TRVN +2.6%, ARMH +2.6%, GPRO +2.5%, SDRL +2.5%, TTM +2.5%, FSLR +2.1%, TOT +2%, RIG +1.9%, SHLM +1.9%, TWTR +1.8%, GRPN +1.8%, MTW +1.3%, GMCR +1.3%, OUBS +1.3%, MSFT +1.2%, RDS.A +1.1%, HAL +0.9%

Gapping down: KBIO -62.3%, LIQT -40.2%, PT -14.7%, MU -3.5%, MDCO -3.4%, SNY -2.6%, AUY -2%, CDR -1.9%, WG -1.5%, KPTI -1.4%, CERS -1.4%, SLV -1.2%, OVAS -1%, GOLD -1%, GD -1%, NEM -1%, GFI -1%

>>> Eli Lilly reaffirms FY14 non-GAAP EPS; guides FY15 EPS towards low end of ex

Eli Lilly reaffirms FY14 non-GAAP EPS; guides FY15 EPS towards low end of expectations, rev just below

Co reaffirms guidance for FY14 (Dec), sees EPS of $2.72-2.80, excluding non-recurring items, vs. $2.78 Capital IQ Consensus.

Co issues guidance for FY15 (Dec), sees EPS of $3.10-3.20, excluding non-recurring items, vs. $3.19 Capital IQ Consensus; sees FY15 (Dec) revs of $20.3-20.8 bln vs. $20.83 bln Capital IQ Consensus.
  • The co expects to grow revenue with a first wave of product launches in diabetes, oncology and immunology followed by a second wave of potential launches in cardiovascular disease, Alzheimer's disease, pain and oncology. The company will focus on key geographies including the U.S., Japan, China and other select markets.
  • Lilly will focus its internal research and development on the core areas of diabetes, oncology, neurodegeneration, immunology and pain. Lilly is also progressing with an ambitious effort to reduce significantly the development time required to bring new medicines to patients.
  • The co aims to turn revenue growth into even greater earnings growth by controlling costs and leveraging existing infrastructure. By driving productivity improvements across the value chain, Lilly expects to reduce total operating expenses as a percent of revenue to 50% or less by the end of 2018.
Q4 financial results will be announced on Jan 30, 2015.

Fwd:>>> Tom Tom - Volkswagen news is pushing the stock up 8%...just the begining

Tom Tom +4% again today...stock should continue to trade higher...very interesting story...I will bet for Auto Parts co like Valero, Faurecia or Continental to try to move on t

From: LAURENT CHEKROUN (MAKOR SECURITIES LLP) At: Jan 6 2015 09:32:41
To: LAURENT CHEKROUN (MAKOR SECURITIES LLP)
Subject: Fwd:>>> Tom Tom - Volkswagen news is pushing the stock up 8%...just the begining
CES in Las Vegas is on and one of the biggest development ans news from Auto maker are that we will not need to drive anymore in the next 5/6y...the car will be able to drive by itself...if this is the new development of the car industry, the mapping will be even more a major data and there is not so many indepenmdant player in the street...as Google is developing its own car service...
Tom Tom is still a mangeable deal with a 1.2bil market cap for many players (Continental, Valeo) or directly for car company...Garmin is a 10bil market cap company...

I think that the stock will continue to outperform...

- Valeo debuts smartwatch, automated driving, and dynamic lighting at 2015 CES
...